Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

833 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2023 ACR/EULAR antiphospholipid syndrome classification criteria.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesús G, Delluc A, Desai S, Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-García A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. Barbhaiya M, et al. Among authors: guillemin f. Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28. Ann Rheum Dis. 2023. PMID: 37640450
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. Barbhaiya M, et al. Among authors: guillemin f. Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28. Arthritis Rheumatol. 2023. PMID: 37635643
Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke.
Chalos V, Venema E, Mulder MJHL, Roozenbeek B, Steyerberg EW, Wermer MJH, Lycklama À Nijeholt GJ, van der Worp HB, Goyal M, Campbell BCV, Muir KW, Guillemin F, Bracard S, White P, Dávalos A, Jovin TG, Hill MD, Mitchell PJ, Demchuk AM, Saver JL, van der Lugt A, Brown S, Dippel DWJ, Lingsma HF; HERMES CollaboratorsMR CLEAN Registry Investigators. Chalos V, et al. Among authors: guillemin f. JAMA Neurol. 2023 Jul 31;80(9):940-8. doi: 10.1001/jamaneurol.2023.2392. Online ahead of print. JAMA Neurol. 2023. PMID: 37523199
Endovascular therapy in acute ischemic stroke with poor reperfusion is associated with worse outcomes compared with best medical management: a HERMES substudy.
Rex N, Ospel JM, Brown SB, McDonough RV, Kashani N, Hill MD, Dippel DWJ, Campbell B, Muir KW, Demchuk AM, Bracard S, Guillemin F, Jovin TG, Mitchell PJ, White P, Majoie CBLM, Saver JL, Goyal M. Rex N, et al. Among authors: guillemin f. J Neurointerv Surg. 2023 Aug 2:jnis-2023-020411. doi: 10.1136/jnis-2023-020411. Online ahead of print. J Neurointerv Surg. 2023. PMID: 37532454
Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challenges.
Joshi M, Darooka N, Saha S, Dyball S, Sen P, Yaadav P, Javaid M, Kadam E, Shinjo SK, Dey D, Cavagna L, Makol A, Gutiérrez CET, Caballero Uribe CV, Kuwana M, Burmester GR, Ziade N, Wincup C, Andreoli L, Parodis I, Tan AL, Guillemin F, Knitza J, Wang G, Dalbeth N, Velikova T, Gracia-Ramos AE, Nikiphorou E, Day J, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD study group. Joshi M, et al. Among authors: guillemin f. Int J Rheum Dis. 2024 May;27(5):e15161. doi: 10.1111/1756-185X.15161. Int J Rheum Dis. 2024. PMID: 38720408
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.
Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J, Wincup C, Andreoli L, Parodis I, Tan AL, Shinjo SK, Dey D, Cavagna L, Chatterjee T, Knitza J, Wang G, Dalbeth N, Velikova T, Battista S, Cheng K, Boyd P, Kobert L, Gracia-Ramos AE, Mittal S, Makol A, Gutiérrez CET, Uribe CVC, Kuwana M, Burmester GR, Guillemin F, Nikiphorou E, Chinoy H, Aggarwal V, Gupta L; COVAD Study Group. Kadam E, et al. Among authors: guillemin f. Rheumatol Int. 2024 Apr 12. doi: 10.1007/s00296-024-05562-z. Online ahead of print. Rheumatol Int. 2024. PMID: 38609655
[Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers].
Guillemin F, Blanchard P, Boisselier P, Brahimi Y, Calugaru V, Coutte A, Gillon P, Graff P, Liem X, Modesto A, Pointreau Y, Racadot S, Sun XS, Bellini R, Pham Dang N, Saroul N, Bourhis J, Thariat J, Biau J, Lapeyre M. Guillemin F, et al. Cancer Radiother. 2024 Apr;28(2):218-227. doi: 10.1016/j.canrad.2023.12.001. Epub 2024 Apr 9. Cancer Radiother. 2024. PMID: 38599940 French.
833 results